Results 161 to 170 of about 15,740 (203)

Personalized Venetoclax Dose Adjustment in Unfit Acute Myeloid Leukemia Patients: A Real-Life Case Series Study. [PDF]

J Pers Med
Luponio S, Serio B, Ferrara I, Gigantiello A, Della Corte AM, Morini D, Conversano I, Verdesca F, Velino F, Sessa AM, Caruso S, Marcucci R, De Leucio M, Giudice V, Langella M, Selleri C.   +15 more
europepmc   +1 more source

Corrigendum to "Sitravatinib combined with venetoclax exerts effective synergy to eliminate acute myeloid leukemia cells with FLT3-ITD mutations" [Translational Oncology 58 (2025) 102467]. [PDF]

Transl Oncol
Yang J, Zhang Y, Li Q, Wang P.
europepmc   +1 more source

Multi‑omics factor analysis reveals a RAS mutant-like metabolically distinct AML subgroup resistant to venetoclax

Schuringa JJ, Sternadt D, Hogeling S, Oudejans L, Rose Nl, Huls G, Peraira-Martins D.   +6 more
europepmc   +1 more source

Differential mitochondrial priming by BCR::ABL1 in B-cell precursor acute lymphoblastic leukemia. [PDF]

Leukemia
Kirchhoff H, Schoenherr C, Fleischer L, Talbot SR, Heidel FH, Bergmann AK, Eder M, Scherr M.   +7 more
europepmc   +1 more source

From cell lines to PDXs: in vivo confirmation of synergistic drug responses identified in leukemia cell line models. [PDF]

Blood Neoplasia
Verbeek TCAI, Vrenken KS, Arentsen-Peters STCJM, van den Hoof E, Pieters R, Stam RW.   +5 more
europepmc   +1 more source

The KDM-family inhibitor JIB-04 sensitizes AML cells to venetoclax by inducing a ferroptosis-like phenotype. [PDF]

Blood Neoplasia
Wohlan K, Fan D, Guzman AG, Quezada A, Park H, Khabusheva E, Sivandzade F, Wither M, Alcorn A, Thevarajah T, Kornblau SM, DiNardo CD, Su J, Goodell MA, Rau RE.   +14 more
europepmc   +1 more source

HDAC8 inhibition targets STAT3-MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia. [PDF]

Leukemia
Zhang L, Guo W, Fu YH, Wu D, Li M, Chen YC, Tseng CY, Hua WK, Nguyen LXT, He X, Dong H, Zhang L, Zhang B, Li L, Marcucci G, Kuo YH.   +15 more
europepmc   +1 more source

Hypomethylating agents plus venetoclax in younger acute myeloid leukemia: Meta-analysis of a shifting treatment paradigm. [PDF]

Cancer
Perrone S, De Fazio L, Monachetti S, Molica M.   +3 more
europepmc   +1 more source

Effects and molecular mechanism of inhibiting p53 signaling pathway by NSUN4 on the resistance to BCL-2 inhibitor for diffuse large B-cell lymphoma. [PDF]

Clin Exp Med
Shi Y, Wen H, Cao T, Zhao Y, Xu Y, Sun J, Zheng X, Jin J, Tong H, Xie W.   +9 more
europepmc   +1 more source

Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial.

Blood
Sharman JP, Laurenti L, Ferrant E, Casado Montero LF, Mulligan SP, Harrup R, Opat S, Ibatici A, Marasca R, Sportoletti P, Thadani-Mulero M, Cazares O, Huang W, Jiang Y, Clark E, Jin HY, Boyer M, Morschhauser F.   +17 more
europepmc   +1 more source